Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada

Erratum

Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada


A. Chua*, MPH, A. Perrin*, BA, J.F. Ricci†, PhD PharmD, M.P. Neary‡, PhD MS, M. Thabane§, PhD MSc


doi: http://dx.doi.org/10.3747/co.25.4233

Original Citation

Curr Oncol 2018;25:32–40. doi:10.3747/co.25.3532.

Published online: 28 February 2018.

Corrected after print: 26 June 2018.

Author Description of the Error

In the initially submitted manuscript, two figures were included:

  • Figure 1, Area-under-the-curve partitioned survival model schema; and

  • Figure 2, Probabilistic sensitivity scatter plot.

In response to the comments from peer reviewers, the authors replaced those two figures in the revised manuscript. The new figures were

  • Figure 1, Parametric survival distributions for progression-free survival and overall survival overlaid on Kaplan–Meier data for everolimus plus best supportive care; and

  • Figure 2, Cost-effectiveness acceptability curve.

However, in the published article, the two figures from the initially submitted manuscript were published in place of the two figures from the revised manuscript, although the captions for the two figures were correctly published (that is, the published captions reflected the revised content of the figures). The error has been corrected in the HTML and PDF versions of the article.

Figures Included in the Initially Submitted Manuscript and the Published Manuscript

 


 

FIGURE 1 Area-under-the-curve partitioned survival model schema.

 


 

FIGURE 2 Probabilistic sensitivity scatter plot.

Figures Included in the Revised Manuscript

 


 

FIGURE 1 Parametric survival distributions for progression-free survival (PFS) and overall survival (OS) overlaid on Kaplan–Meier (KM) data for everolimus plus best supportive care.

 


 

FIGURE 2 Cost-effectiveness acceptability curve. CAD = Canadian dollars.


Correspondence to: Marroon Thabane, Health Economics and Patient Access, Novartis Pharmaceuticals Canada Inc., 385 Bouchard Boulevard, Dorval, Quebec H9S 1A9. E-mail: marroon.thabane@novartis.com

(Return to Top)



Current Oncology, VOLUME 25, NUMBER 4, August 2018








Copyright © 2018 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)